Brokerages Set Indivior PLC (NASDAQ:INDV) Price Target at $39.33

Posted by on Jun 19th, 2026

Shares of Indivior PLC (NASDAQ:INDV – Get Free Report) have been given an average rating of “Buy” by the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $40.2857.

Several equities research analysts recently issued reports on INDV shares. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Finally, Barclays began coverage on shares of Indivior in a research note on Thursday. They issued an “overweight” rating and a $46.00 price objective for the company.

Get Our Latest Analysis on INDV

Insiders Place Their Bets

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer owned 284,751 shares in the company, valued at approximately $10,735,112.70. This represents a 11.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.74% of the company’s stock.

Hedge Funds Weigh In On Indivior

Large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its stake in shares of Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after acquiring an additional 1,299,425 shares during the period. Jane Street Group LLC raised its stake in Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after purchasing an additional 958,132 shares during the period. JPMorgan Chase & Co. lifted its holdings in Indivior by 669.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock worth $5,769,000 after purchasing an additional 340,498 shares in the last quarter. Prudential Financial Inc. purchased a new position in Indivior in the 2nd quarter worth approximately $207,000. Finally, Walleye Capital LLC bought a new position in Indivior in the 2nd quarter worth approximately $594,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Stock Performance

NASDAQ INDV opened at $38.28 on Friday. The business’s fifty day moving average is $36.06 and its 200 day moving average is $34.44. Indivior has a fifty-two week low of $13.45 and a fifty-two week high of $41.00. The company has a market capitalization of $4.67 billion, a PE ratio of 19.63 and a beta of 0.88.

Indivior (NASDAQ:INDV – Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The business had revenue of $317.00 million during the quarter. On average, sell-side analysts forecast that Indivior will post 4.05 EPS for the current year.

About Indivior

(Get Free Report)

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.

Featured Articles

Analyst Recommendations for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.